Latest Insider Transactions at Biolife Solutions Inc (BLFS)
This section provides a real-time view of insider transactions for Biolife Solutions Inc (BLFS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOLIFE SOLUTIONS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOLIFE SOLUTIONS INC's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 18
2022
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
16,413
-13.24%
|
$279,021
$17.59 P/Share
|
Apr 18
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
24,400
-6.34%
|
$414,800
$17.59 P/Share
|
Apr 13
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
10,000
-2.53%
|
$190,000
$19.06 P/Share
|
Apr 13
2022
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.47%
|
$10,000
$1.9 P/Share
|
Apr 12
2022
|
Karen A. Foster Chief Quality and Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
38,836
+23.86%
|
-
|
Apr 12
2022
|
Roderick De Greef President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
43,846
+22.82%
|
-
|
Apr 12
2022
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,136
+20.77%
|
-
|
Apr 12
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
45,726
+14.43%
|
-
|
Apr 12
2022
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
57,736
+13.04%
|
-
|
Apr 11
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
10,000
-2.97%
|
$190,000
$19.55 P/Share
|
Apr 11
2022
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.88%
|
$10,000
$1.9 P/Share
|
Apr 07
2022
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
10,713
-9.3%
|
$224,973
$21.82 P/Share
|
Mar 29
2022
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
475
-0.52%
|
$10,450
$22.24 P/Share
|
Mar 29
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
830
-0.25%
|
$18,260
$22.24 P/Share
|
Mar 29
2022
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
547
-0.64%
|
$12,034
$22.24 P/Share
|
Mar 29
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
658
-0.29%
|
$14,476
$22.24 P/Share
|
Mar 22
2022
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
551
-1.23%
|
$12,673
$23.06 P/Share
|
Mar 09
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
10,000
-2.96%
|
$230,000
$23.81 P/Share
|
Mar 09
2022
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.87%
|
$10,000
$1.9 P/Share
|
Mar 07
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
10,000
-2.96%
|
$230,000
$23.8 P/Share
|
Mar 07
2022
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.87%
|
$10,000
$1.9 P/Share
|
Mar 01
2022
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
56
-0.26%
|
$1,288
$23.78 P/Share
|
Mar 01
2022
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
221
-0.32%
|
$5,083
$23.78 P/Share
|
Mar 01
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
874
-0.34%
|
$20,102
$23.78 P/Share
|
Mar 01
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
412
-0.2%
|
$9,476
$23.78 P/Share
|
Feb 24
2022
|
Marcus Schulz Chief Revenue Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,019
+24.92%
|
-
|
Feb 24
2022
|
Sarah Aebersold Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,019
+29.78%
|
-
|
Feb 24
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,029
+8.49%
|
-
|
Feb 24
2022
|
Michael Rice |
BUY
Grant, award, or other acquisition
|
Direct |
70,094
+17.57%
|
-
|
Feb 24
2022
|
Roderick De Greef President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,365
+16.86%
|
-
|
Feb 24
2022
|
Karen A. Foster Chief Quality and Operations |
BUY
Grant, award, or other acquisition
|
Direct |
16,356
+16.0%
|
-
|
Feb 24
2022
|
Todd Berard Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,019
+13.36%
|
-
|
Feb 24
2022
|
Troy Wichterman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,365
+34.3%
|
-
|
Feb 15
2022
|
Troy Wichterman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
695
-3.15%
|
$18,070
$26.57 P/Share
|
Feb 10
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
450
-0.22%
|
$13,050
$29.38 P/Share
|
Feb 10
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
690
-0.27%
|
$20,010
$29.38 P/Share
|
Feb 10
2022
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
293
-0.42%
|
$8,497
$29.38 P/Share
|
Feb 10
2022
|
Sarah Aebersold Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
197
-1.02%
|
$5,713
$29.38 P/Share
|
Feb 10
2022
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
254
-0.33%
|
$7,366
$29.38 P/Share
|
Feb 10
2022
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
167
-0.59%
|
$4,843
$29.38 P/Share
|
Feb 03
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
16,670
-6.04%
|
$450,090
$27.84 P/Share
|
Feb 03
2022
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
16,670
+5.69%
|
$16,670
$1.78 P/Share
|
Feb 03
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,837
-4.56%
|
$265,599
$27.76 P/Share
|
Feb 03
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,837
+4.36%
|
$19,674
$2.06 P/Share
|
Feb 02
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
10,000
-4.63%
|
$290,000
$29.88 P/Share
|
Feb 02
2022
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.42%
|
$30,000
$3.7 P/Share
|
Feb 01
2022
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
16,666
-6.04%
|
$483,314
$29.9 P/Share
|
Feb 01
2022
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
16,666
+5.69%
|
$16,666
$1.78 P/Share
|
Jan 20
2022
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
395
-1.37%
|
$11,850
$30.24 P/Share
|
Jan 20
2022
|
Sarah Aebersold Chief Human Resources Officer |
SELL
Open market or private sale
|
Direct |
332
-1.7%
|
$9,960
$30.24 P/Share
|